Answers are grounded in this paper and cite their sources.
The benefits of cytomegalovirus (CMV) prophylaxis in preventing the direct effects of CMV infection and disease are well established; however, the impact of exposure to antiviral agents on preventing the indirect effects of CMV infection are poorly defined. This article reviews the results of current studies demonstrating the benefits of CMV prophylaxis in reducing the risks of indirect effects of CMV infection: acute and chronic allograft rejection, graft failure, patient mortality, cardiac complications and atherosclerosis, and posttransplant lymphoproliferative disorder, in solid organ transplant recipients.
No takes yet. Share an insight, caveat, or question.
Mark D. Pescovitz (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: